- Home
- HCM vs DNLI Comparison
HCM vs DNLI Comparison
Compare HCM & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HCM | DNLI |
|---|---|---|
| Founded | 2000 | 2013 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.5B |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | HCM | DNLI |
|---|---|---|
| Price | $14.13 | $20.11 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 1 | 13 |
| Target Price | $13.75 | ★ $32.64 |
| AVG Volume (30 Days) | 29.0K | ★ 1.4M |
| Earning Date | 08-07-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.53 | N/A |
| Revenue | ★ $602,197,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $15.54 | $94,232.03 |
| P/E Ratio | $5.26 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $11.51 | $10.57 |
| 52 Week High | $19.50 | $26.18 |
Technical Indicators
Market Signals| Indicator | HCM | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 37.46 | 68.58 |
| Support Level | $14.11 | $17.65 |
| Resistance Level | $14.63 | $19.63 |
| Average True Range (ATR) | 0.27 | 1.02 |
| MACD | -0.01 | 0.14 |
| Stochastic Oscillator | 21.69 | 95.82 |
Price Performance
Historical ComparisonAbout HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.